How Do You Build A Clinical Trial Network Focused On Diversity?

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

Stakeholders discuss network models, barriers to their creation, and what is needed for them to be successful at PhRMA meeting.

Diversity
Pharma aims to expand clincial trial diversity through networks • Source: Alamy

Dramatically boosting enrollment of minority populations in clinical trials has become a top goal of the pharmaceutical industry. One way to achieve this is by building a network of clinical trial sites focused on diversity. But stakeholders say there are many hurdles to establishing networks and note the need for partnerships to create community-based infrastructures.

“Existing clinical trial networks have been designed largely to be siloed,” Doug Peddicord, executive director of the Association of Clinical...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By Vibha Sharma

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

More from R&D

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By Vibha Sharma

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By Sue Sutter

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.